RPE65 and Leber congenital amaurosis: Luxturna (voretigene neparvovec-rzyl) is currently the only gene therapy in ophthalmology approved by both the FDA and the EU for the treatment of patients with Leber congenital amaurosis caused by mutations in the RPE65 gene.